MindImmune Therapeutics agrees to acquire two programs from H. Lundbeck

MINDIMMUNE THERAPEUTICS has entered into an agreement with Lundbeck tow acquire two programs related to neuropathic pain and Huntington's disease. / COURTESY MINDIMMUNE THERAPEUTICS
MINDIMMUNE THERAPEUTICS has entered into an agreement with Lundbeck tow acquire two programs related to neuropathic pain and Huntington's disease. / COURTESY MINDIMMUNE THERAPEUTICS
SOUTH KINGSTOWN –MindImmune Therapeutics Inc. has entered into agreements with H. Lundbeck A/S to acquire programs and will develop candidates from these programs as novel therapeutics to treat neuropathic pain and Huntington’s disease, the company announced Wednesday. The programs target two neuroinflammation targets: P2X7 receptors and KMO, an enzyme in the neuroimmune kynurenine-signaling pathway, according…

Want More?

Subscribe or register with Providence Business News to keep reading.

REGISTER
for 2 more stories

Subscribe now for $1 for 4 weeks
Already a Subscriber? Login now

Purchase NowWant to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.

- Advertisement -

No posts to display